China’s NMPA approves Zai Lab’s XACDURO NDA for pneumonia
Zai Lab and Innoviva Specialty Therapeutics have announced the approval of China’s National Medical Products Administration (NMPA) for Zai’s new drug application (NDA) submitted for XACDURO (sulbactam-durlobactam) to treat hospital-acquired bacterial …